Drugs / Miricorilant
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials · 1 met primary | ||||||
| Phase 1 | NCT07553663 | Apr → Oct 2026 expected | NAFLD1, metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT07240116 | Sep 2025 → Mar 2026 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06947304 | Aug 2025 → Aug 2026 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05712265 | Jan → Feb 2023 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05553470 | Mar 2022 → Sep 2024 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05117489 | Nov 2021 → Jan 2024 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04672499 | Apr → Sep 2020 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03877562 | Apr 2019 → Mar 2020 | acquired hypothalamic obesity | Corcept Therapeutics | Completed | Met primary |
| Phase 1 | NCT03878264 | Aug 2018 → Mar 2019 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03315338 | Sep 2017 → Feb 2019 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT06108219 | Oct 2023 → Feb 2026 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03823703 | Nov 2020 → Apr 2021 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04524403 | Sep 2020 → Jul 2022 | — | Corcept Therapeutics | Completed | Missed primary |
| Phase 2 | NCT03818256 | Dec 2019 → Jun 2022 | — | Corcept Therapeutics | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04466215 Comparator | Apr 2021 → Apr 2022 | alcohol-related disorders | The Scripps Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2023-07-17 | Corcept Therapeutics | Results Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH) corcept.com ↗
today announced topline results from a Phase 1b study evaluating its proprietary cortisol modulator, miricorilant, in patients with presumed non-alcoholic steatohepatitis (NASH). |
| 2022-12-08 | Corcept Therapeutics | Results Corcept Therapeutics Provides Miricorilant Clinical Development Update corcept.com ↗
Miricorilant did not reverse AIWG in either our GRATITUDE or GRATITUDE II trials,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. |
| 2021-11-03 | Corcept Therapeutics | Results Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update corcept.com ↗
patients with presumed-NASH who received miricorilant experienced exceptionally large and rapid reductions in liver fat |
| 2021-05-06 | Corcept Therapeutics | Results Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results corcept.com ↗
In Phase 2 trial, patients with presumed nonalcoholic steatohepatitis (NASH) administered miricorilant experienced large, rapid reductions in liver fat |
| 2021-05-06 | Corcept Therapeutics | Results Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH) corcept.com ↗
today announced interim findings from the Phase 2 trial of its selective cortisol modulator miricorilant in patients with presumed NASH. |
| 2020-05-04 | Corcept Therapeutics | Results Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update corcept.com ↗
No side effects, beyond those seen with olanzapine, were observed. |
| 2019-11-07 | Corcept Therapeutics | Results Corcept Therapeutics Announces Third Quarter 2019 Financial Results and Provides Corporate Update corcept.com ↗
In a double-blind, placebo-controlled trial in healthy subjects, our selective cortisol modulator miricorilant significantly reduced the weight gain caused by the commonly prescribed antipsychotic medication olanzapine (Eli Lily’s drug, Zyprexa®). |
All press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Miricorilant | “This study will evaluate relative bioavailability of Kinetisol and spray dried dispersion (SDD) miricorilant (CORT118335) tablets.” NCT07240116 ↗11“Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing” NCT04524403 ↗ |
| Known as | CORT118335 | “miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with antipsychotic medications” NCT03818256 ↗ |
| Modality | Small molecule | — CHEMBL4297602 ↗ |
| Route | Oral | “CORT118335 is supplied as capsules for oral dosing” NCT03315338 ↗ |